Drug intelligence / Profile preview

ATH-131

Development stage: Preclinical
Lead developer: Athos Therapeutics
Modality: Small Molecules

Overview

ATH-131 is a small molecule drug initially developed by Athos Therapeutics, Inc. It is being investigated for the treatment of immune system diseases, digestive system disorders, and eye diseases. The primary active indications include inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis), Sjogren’s syndrome, and systemic lupus erythematosus. As of March 2025, its highest global R&D status is preclinical[1][2]. The specific mechanism of action has not been publicly disclosed in available sources.

Beyond the preview

Go deeper on ATH-131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATH-131.

Explore the full profile